90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
Titel:
90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study
Auteur:
Chevallier, Patrice Eugene, Thomas Robillard, Nelly Isnard, Françoise Nicolini, Franck Escoffre-Barbe, Martine Huguet, Françoise Hunault, Mathilde Marcais, Antoine Gaschet, Joelle Cherel, Michel Guillaume, Thierry Delaunay, Jacques Peterlin, Pierre Eveillard, Marion Thomas, Xavier Ifrah, Norbert Lapusan, Simona Bodet-Milin, Caroline Barbet, Jacques Faivre-Chauvet, Alain Ferrer, Ludovic Bene, Marie C Le Houerou, Claire Goldenberg, David M Wegener, William A Kraeber-Bodéré, Françoise